Damon Wang

Chief Executive Officer Nucyrna Therapeutics

Damon Wang, PhD is the Co-founder and CEO of NuCyRNA Therapeutics, a biotech startup with a bold vision to transform RNA-targeting therapeutics, with current focus on neurodegenerative diseases.

Additionally, Dr. Wang has been deeply engaged in the biotech investment community. From 2020 to 2023, he served as a consultant to several biotech venture capital firms, advising on RNA therapeutics. Earlier, in 2018, he co-founded Bioeconomy, a venture dedicated to connecting U.S. biotech entrepreneurs with international investors.

He earned his PhD in RNA therapeutics at the UMass RNA Therapeutics Institute, where he specialized in RNA engineering, with a focus on siRNA, antisense oligonucleotide (ASO), and mRNA technologies.

Seminars

Wednesday 27th January 2027
Engineering Novel Targeted Muscle Delivery Technologies to Enhance Oligonucleotide Delivery & Biodistribution
2:00 pm
  • Moving towards delivery platforms that enhance payload delivery to increase efficient drug delivery
  • Addressing poor specificity and the consequences of long-term drug accumulation
  • Exploring how we can achieve more accurate delivery and trafficking characteristics to the muscle for DM1 therapies
Meet Damon Wang, speaking at the Muscular Disorders Drug Development Summit on advancing innovative therapies for muscle diseases.
View all Speakers
View Event Brochure